Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts

Planet MicroCap spoke with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ: COCP) via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all):

[0:29] Overview and history of Cocrystal Pharma, Inc.
[1:43] Target indications and clinical development
[6:24] What makes Cocrystal's compounds and formulas unique and different compared to their peers
[9:14] 2024 value catalysts moving forward

For more information about Cocrystal Pharma, Inc., please visit: https://www.cocrystalpharma.com/

The interview may contain forward looking statements about Cocrystal Pharma, Inc. See Cocrystal Pharma, Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Subscribe NOW to Planet MicroCap: http://bit.ly/1Q5Yfym

Get more Planet MicroCap:
Website: https://planetmicrocap.com/
Follow Planet MicroCap:   / planetmicrocap  
Like Planet MicroCap:   / planetmicrocap  
Follow Planet MicroCap on LinkedIn:   / plan.  .

Planet MicroCap is the Official YouTube Channel for the MicroCap markets by providing news, insights, education tools and expert commentary. Subscribe now to be notified when new CEO video interviews, WALL STREET VIEWS with investing experts and new episodes of the Planet MicroCap Podcast are LIVE!